| Aliskiren | heart failure, in acute decompensated heart failure | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Trial | Studied treatment | Control | Patients |
|---|
| ASTRONAUT, 2013 | Aliskiren | placebo | stable patients with heart failure, an LVEF <40% (mean 28%), and elevated natriuretic peptides who had been discharged from a heart-failure hospitalization an average of five days before |
| |
| Aliskiren | hypertension, in all type of patients | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| cardiovascular events | no data | | Serious adverse event | 0.95 [0.55 1.66] | p=1.00 | 0 | 599 | 1 | AVOID, | | any adverse event | 0.99 [0.71 1.40] | p=1.00 | 0 | 599 | 1 | AVOID, | | All cause death | 0.20 [0.01 4.14] | p=1.00 | 0 | 599 | 1 | AVOID, | | Adverse events leading to treatment discontinuation | 0.89 [0.45 1.74] | p=1.00 | 0 | 599 | 1 | AVOID, |
| Trial | Studied treatment | Control | Patients |
|---|
| AVOID, 2008 | aliskiren (150 mg daily for 3 months, followed by an increase in dosage to 300 mg daily for another 3 months | placebo | patients with hypertension and type 2 diabetes with nephropathy |
| |
| Aliskiren | | vs losartan | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| cardiovascular events | no data | | Serious adverse event | 0.76 [0.32 1.79] | p=1.00 | 0 | 306 | 1 | ALLAY, | | any adverse event | 1.10 [0.70 1.72] | p=1.00 | 0 | 306 | 1 | ALLAY, | | All cause death | 0.99 [0.02 50.07] | p=1.00 | 0 | 306 | 1 | ALLAY, | | Adverse events leading to treatment discontinuation | 0.39 [0.12 1.29] | p=1.00 | 0 | 306 | 1 | ALLAY, |
| Trial | Studied treatment | Control | Patients |
|---|
| ALLAY, 2009 | aliskiren 300 mg | losartan 100 mg | patients with hypertension, increased ventricular wall thickness, and body mass index >25 kg/m2 |
| |
| Aliskiren | | vs ramipril | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| cardiovascular events | no data | | Serious adverse event | no data | | any adverse event | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| Andersen, 2008 | aliskiren 150 mg (up to 300mg) daily | ramipril 5 mg (up to 10mg) daily | |
| |
| Aliskiren | | vs hydrochlorothiazide | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| cardiovascular events | no data | | Serious adverse event | 1.17 [0.65 2.08] | p=1.00 | 0 | 1124 | 1 | Schmieder (vs HCTZ), | | any adverse event | 1.06 [0.83 1.35] | p=1.00 | 0 | 1124 | 1 | Schmieder (vs HCTZ), | | All cause death | no data | | Adverse events leading to treatment discontinuation | 0.70 [0.43 1.14] | p=1.00 | 0 | 1124 | 1 | Schmieder (vs HCTZ), |
| Trial | Studied treatment | Control | Patients |
|---|
| Schmieder (vs HCTZ), 2009 | aliskiren 300 mg | hydrochlorothiazide 25 mg | patients with essential hypertension |
| |
| Aliskiren | hypertension, in diabetic patients | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| cardiovascular events | no data | | Serious adverse event | 0.95 [0.55 1.66] | p=1.00 | 0 | 599 | 1 | AVOID, | | any adverse event | 0.99 [0.71 1.40] | p=1.00 | 0 | 599 | 1 | AVOID, | | All cause death | 0.20 [0.01 4.14] | p=1.00 | 0 | 599 | 1 | AVOID, | | Adverse events leading to treatment discontinuation | 0.89 [0.45 1.74] | p=1.00 | 0 | 599 | 1 | AVOID, |
| Trial | Studied treatment | Control | Patients |
|---|
| AVOID, 2008 | aliskiren (150 mg daily for 3 months, followed by an increase in dosage to 300 mg daily for another 3 months | placebo | patients with hypertension and type 2 diabetes with nephropathy |
| |
